3056570-19-2
Chemical Structure
AZ'9567
- CAS No.: 3056570-19-2
- Formula:C24H19F2N5O2
- Molecular Weight:447.44
InChIKey: QEASMQZYZCGOSA-UHFFFAOYSA-N
SMILES: O=C1C(C2=CC3=CN(C)N=C3C=C2)=CC(NN=C4C5CC5)=C4N1C6=CC=C(OC(F)F)C=C6
Biological Activity: AZ'9567 is an orally active MAT2a inhibitor with a pIC50 of 9.1. AZ'9567 binds to MAT2a allosterically, reduces the synthesis of SAM, decreases SDMA levels, and exerts antiproliferative effects on MTAP-knockout cells. AZ'9567 depletes SAM, causes methionine accumulation in plasma and tissues, triggers adaptive disorders in one-carbon metabolism, transsulfuration metabolism and lipid metabolism, and induces oxidative stress, hepatic steatosis and lipid homeostasis imbalance. AZ'9567 can be used in studies related to MTAP-deficient/deleted cancers[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AZ'9567 | 99.19% | AZ'9567 is an orally active MAT2a inhibitor with a pIC50 of 9.1. AZ'9567 binds to MAT2a allosterically, reduces the synthesis of SAM, decreases SDMA levels, and exerts antiproliferative effects on MTAP-knockout cells. AZ'9567 depletes SAM, causes methionine accumulation in plasma and tissues, triggers adaptive disorders in one-carbon metabolism, transsulfuration metabolism and lipid metabolism, and induces oxidative stress, hepatic steatosis and lipid homeostasis imbalance. AZ'9567 can be used in studies related to MTAP-deficient/deleted cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Atkinson SJ, et al. Development of a Series of Pyrrolopyridone MAT2A Inhibitors. J Med Chem. 2024;67(6):4541-4559. [Content Brief]
- [2]. Fogal V, et al. Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition. Arch Toxicol. 2024;98(8):2589-2603. [Content Brief]
- [3]. Yang S, et al. Discovery of Novel Spirocyclic MAT2A Inhibitors Demonstrating High In Vivo Efficacy in MTAP-Null Xenograft Models. J Med Chem. 2025;68(3):3480-3494. [Content Brief]
Keywords
